
Arvind Srinivas
41 posts

Arvind Srinivas
@arv9293
Standard career by day, investment explorer by night. Here to exchange ideas, discussions, strategy around long-term capital appreciation. Not an advisor












Bought 1,000 shares of $NVO at $41 + 20 Jan 2027 LEAPS at the $40/$50 strikes. Thesis is simple. $LLY owns the "best drug" narrative. $NVO might own the "drug people can actually afford" narrative. The obesity market is MASSIVE. With 60% of people having to pay out of pocket. Novo's cash-pay Wegovy pen runs $199 intro, then $349/mo. Oral Wegovy starts at $149/mo on lower doses. Lilly's Zepbound is $299/mo at 2.5mg, $399 at 5mg, and $449 at the higher doses. So yes, $LLY has the stronger efficacy story with tirzepatide and retatrutide. But $NVO has: Ozempic brand recognition Wegovy brand recognition oral semaglutide a cheaper entry point a beaten down valuation



















